TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05042609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRS01
Description: TRS01 eye drops Dosed four times a day (QID)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FDA approved steroid eye drop (masked)
Description: FDA approved steroid eye drop Dosed four times a day (QID)
Study: NCT06371534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL2109
Description: subcutaneous injection 3-5 min D1 (Day 1, single dose)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DARZALEX FASPRO®
Description: subcutaneous injection 3-5 min D1 (Day 1, single dose)
Study: NCT05792683

Intervention type: DEVICE
Group type: OTHER
Intervention: lumbar drain
Description: Patient will be placed in the lateral decubitus position; catheter will be inserted by using a Tuohy needle in the interspinous area of lumbar spine. The LD catheter will reach the lumbar subarachnoid space.The remaining part of the drainage kit will be placed along the back of the patient. The catheter insertion site will be sutured and treated with povidone-iodine ointment. Sterile drape will be used to cover the entire external part of the LD.~The CSF will be collected within the closed beg. CSF drainage through LD will be around 10 ml per hour or 200-250 ml/day.
Study: NCT05505604

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PENG
Description: patients will receive an ultrasound-guided Pericapsular Nerve Group Block with 20mL of 0.25% bupivacaine (not to exceed 2mg/kg)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FICB
Description: Patients will receive an ultrasound-guided Fascia Iliaca Compartment Block with 20 mL of 0.25% bupivacaine (not to exceed 2 mg/kg) diluted to total volume of 40 mL of injectate
Study: NCT05224037

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: iLivTouch
Description: Eligible subjects will undergo liver stiffness and controlled attenuation parameters examination with two devices on the same day
Study: NCT05989659

Intervention type: OTHER
Intervention: Exposure: Home dialysis or facility-hemodialysis
Description: Initiation of dialysis with home dialysis (peritoneal dialysis or home hemodialysis) or facility-hemodialysis

Intervention type: OTHER
Intervention: Exposure: Home dialysis or facility-hemodialysis
Description: Initiation of dialysis with home dialysis (peritoneal dialysis or home hemodialysis) or facility-hemodialysis

Intervention type: OTHER
Intervention: Exposure: Home dialysis or facility-hemodialysis
Description: Initiation of dialysis with home dialysis (peritoneal dialysis or home hemodialysis) or facility-hemodialysis

Intervention type: OTHER
Intervention: Exposure: Home dialysis or facility-hemodialysis
Description: Initiation of dialysis with home dialysis (peritoneal dialysis or home hemodialysis) or facility-hemodialysis
Study: NCT05378074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maxipost
Description: Study participants will be allocated to receive continuous intravenous infusion of 0.05 mg/min MaxiPost.
Study: NCT05234489

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Signature Cord Prime
Description: Low dose - Subjects will receive SIG001 (75 mg) which will be diluted to a total of 4 ml volume with Ringer's Lactate.~High dose - Subjects will receive SIG001 (150mg) which will be diluted to a total of 4 ml volume with Ringer's Lactate.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Signature Cord Prime
Description: Low dose - Subjects will receive SIG001 (75 mg) which will be diluted to a total of 4 ml volume with Ringer's Lactate.~High dose - Subjects will receive SIG001 (150mg) which will be diluted to a total of 4 ml volume with Ringer's Lactate.
Study: NCT05947682

Intervention type: OTHER
Group type: OTHER
Intervention: Adipose tissue harvesting
Description: Adipose tissue harvesting (40-60g) during the abdominal liposuction or lipoaspiration under general anaesthesia which is performed according to usual care
Study: NCT05161169

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genome Sequencing
Description: 20 times read depth (20x) next-generation whole genome sequencing with comprehensive analysis.
Study: NCT06052943

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Intervention
Description: Learning 2 BREATHE (L2B) is an evidence based curriculum for adolescents. L2B in this program consists of 6 sessions of approximately 1 hour per session. In between sessions, participants are asked to practice brief mindfulness skills individually.
Study: NCT05909618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizanlizumab-Tmca 10 MG/1 ML Intravenous Solution [ADAKVEO]
Description: 5 mg/kg solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizanlizumab-Tmca 10 MG/1 ML Intravenous Solution [ADAKVEO]
Description: 5 mg/kg solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizanlizumab-Tmca 10 MG/1 ML Intravenous Solution [ADAKVEO]
Description: 5 mg/kg solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 10 MG/1 ML Intravenous Solution [OPDIVO]
Description: 3 mg/mL solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 10 MG/1 ML Intravenous Solution [OPDIVO]
Description: 3 mg/mL solution for injection
Study: NCT06052943

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Education
Description: The parent education curriculum includes 3 modules: 1) family support/parenting, 2) nutrition and 3) physical activity. The parents set weekly goals to implement the parent education lessons into everyday living.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Combines aerobic and resistance training though game play.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Mindfulness Intervention for Parents
Description: Parent-based mindfulness education based on the Learning to BREATHE curriculum.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preschool Curriculum
Description: Preschool age children learn about and try new foods.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cooking Matters
Description: Nutrition education and hands-on cooking lessons for the whole family
Study: NCT06405906

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fat-free diet
Description: The low-fat diet will consist of instructions to avoid fatty foods.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fat-free diet
Description: The low-fat diet will consist of instructions to avoid fatty foods.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fat-free diet
Description: The low-fat diet will consist of instructions to avoid fatty foods.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fat-free diet
Description: The low-fat diet will consist of instructions to avoid fatty foods.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balanced WHO diet
Description: The balanced WHO diet will adhere to the recommendations of the World Health Organization (WHO) and the Dietary Guidelines for Americans 2020-2025

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balanced WHO diet
Description: The balanced WHO diet will adhere to the recommendations of the World Health Organization (WHO) and the Dietary Guidelines for Americans 2020-2025

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balanced WHO diet
Description: The balanced WHO diet will adhere to the recommendations of the World Health Organization (WHO) and the Dietary Guidelines for Americans 2020-2025

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balanced WHO diet
Description: The balanced WHO diet will adhere to the recommendations of the World Health Organization (WHO) and the Dietary Guidelines for Americans 2020-2025
Study: NCT05378074

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study participants will be allocated to receive continuous intravenous infusion of 20 mL placebo (isotonic saline).
Study: NCT05878106

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Description: 5 g/day supplementation of creatine for the duration of the exercise the 16-week intervention.~The RG and the RCG will receive a supplement of soluble protein powder (20-30 g) daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: They will do resistance training. Resistance training will be a 16-week supervised workout that will consist of a series of resistance exercises (leg press, knee extension, knee bends, chest press, sit-ups, back extensions, pull-ups, and shoulder press) that involved the largest muscle groups of the body and will be performed three times a week on non-consecutive days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: They will do resistance training. Resistance training will be a 16-week supervised workout that will consist of a series of resistance exercises (leg press, knee extension, knee bends, chest press, sit-ups, back extensions, pull-ups, and shoulder press) that involved the largest muscle groups of the body and will be performed three times a week on non-consecutive days.
Study: NCT05571774

Intervention type: OTHER
Intervention: collection data
Description: collection data
Study: NCT05161689

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HUG-M+
Description: A multicomponent, multi-level, community mobilization, combination intervention (HUG-M+) to address the entire HIV Continuum of Prevention and Care.
Study: NCT06216249

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PSMA PET/CT, SPECT/CT, PET/CT and CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo PSMA PET/CT, SPECT/CT, PET/CT and CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68 Gozetotide
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gallium Ga 68 Gozetotide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium Lu 177 Vipivotide Tetraxetan
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lutetium Lu 177 Vipivotide Tetraxetan
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSMA PET Scan
Description: Undergo PSMA PET/CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PSMA PET Scan
Description: Undergo PSMA PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography
Description: Undergo SPECT/CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single Photon Emission Computed Tomography
Description: Undergo SPECT/CT
Study: NCT05938036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT-100 mAb
Description: Experimental: Part A : ALT-100 mAB (Dose Escalation) 90 eligible participants will be randomized at a 2:1 ratio to receive a single dose of ALT-100 mAb.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT-100 mAb
Description: Experimental: Part A : ALT-100 mAB (Dose Escalation) 90 eligible participants will be randomized at a 2:1 ratio to receive a single dose of ALT-100 mAb.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ALT-100 (Placebo)
Description: Normal saline solution via IV solution
Study: NCT06380127

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: The exercise intervention will take place at the nursing homes and consists of 12 weeks of supervised concurrent exercise training, performed thrice weekly on nonconsecutive days to avoid overtraining and fatigue. Each session will last 50-60 min and consist of a warm-up, resistance plus aerobic training, and a 5-min cool-down period. The resistance training will comprise 2-3 sets of 10 to 15 repetitions with a load equivalent to 40 to 70% of the 1-repetition maximum (1RM) for upper (i.e., bicep curl) and lower body exercises (i.e., seated knee extension). The sit-to-stand exercise will be performed as fast as possible according to each participant's capacity without external load. The recovery between sets is between 1 and 2 min. Afterwards, participants will perform walking exercises with changes in pace and direction. The duration of the aerobic training will progress from 5-10 min duration in the first weeks to 10-15 min. The sessions will end with stretching exercises.The exercise
Study: NCT04736615

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAFEWATER systems for drinking water disinfection
Description: A domestic water purification technology, consisting of a raw water storage tank, a pump, a filtration unit (2 cartridge filters), a UVC disinfection unit (UV lamp), a storage tank for drinking water (treated and safe water), and a distribution network inside the house for drinking water.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior change interventions
Description: Targeting behaviors around the use of the technology and water more generally. Behavioral interventions will be data-driven (i.e., dependent on the problems that arise) but are likely to include household and community-level activities.
Study: NCT06301620

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine rehabilitation treatment
Description: Routine rehabilitation treatment Includes oral rehabilitation, rehabilitation training for temporomandibular disorders, orthodontic treatment, and other physical therapy methods.which can alleviate symptoms by adjusting the bite, relaxing muscles, and increasing the range of motion of the temporomandibular joint.~Besides, it also Includes temporomandibular joint exercise training, relaxation training for facial muscles, and functional chewing training aimed at improving temporomandibular joint function and muscle balance.
Study: NCT05494073

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL Reconstruction with Hybrid Remnant Repair
Description: The intervention includes the incorporation of the host ACL remnant into the graft. The intervention hopefully

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL Reconstruction without Hybrid Remnant Repair
Description: ACL reconstruction without preservation or incorporation of host ACL remnant
Study: NCT04851678

Intervention type: OTHER
Intervention: None - observational study
Description: None - observational study
Study: NCT06301620

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine rehabilitation treatment
Description: Routine rehabilitation treatment Includes oral rehabilitation, rehabilitation training for temporomandibular disorders, orthodontic treatment, and other physical therapy methods.which can alleviate symptoms by adjusting the bite, relaxing muscles, and increasing the range of motion of the temporomandibular joint.~Besides, it also Includes temporomandibular joint exercise training, relaxation training for facial muscles, and functional chewing training aimed at improving temporomandibular joint function and muscle balance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intra-articular Injection
Description: The patient is positioned to maximize mouth opening, and a needle is inserted approximately 10-12 mm in front of the tragus after touching the ankle prominence. An 8# injection needle is chosen and inserted upward and slightly forward into the joint cavity. A total of 2 mL of lidocaine hydrochloride injection solution is injected, repeated once every 5 days for a total of 15 days.
Study: NCT06457893

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The health belief model-based exercise training program and health belief model-based education
Description: The health belief model-based exercise training program and education program will implement with the students in the experimental group for 5 weeks and follow-ups will be made at the 3rd and 6th months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The health belief model-based exercise training program and health belief model-based education
Description: The health belief model-based exercise training program and education program will implement with the students in the experimental group for 5 weeks and follow-ups will be made at the 3rd and 6th months.
Study: NCT06334224

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low load resistance training with blood flow restriction
Description: The intervention involves placing a pneumatic tourniquet system over the proximal thigh. The cuff is inflated to 80% of limb occlusion pressure during lower limb strengthening exercises. These exercises include leg press and knee extensor exercises. Four sets (30,15,15,15 repetitions) performed at 20% of one repetition maximum.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low load resistance training
Description: Leg press and knee extensor exercises. Four sets (30,15,15,15 repetitions) performed at 20% of one repetition maximum.
Study: NCT05474222

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Horizon Eagle Fatherhood Program - classroom instruction
Description: The intervention group (the Horizon Eagle Fatherhood Programming) receives 40 hours of classroom instruction
Study: NCT05141461

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Group C
Description: Patients will receive 2 mg midazolam and 50 ug fentanyl for sedation before the block procedure. Each patient will be positioned appropriately, then a high-frequency linear array transducer (13-6 MHz) will be placed in the interscalene region to define the brachial plexus on the short axis. Under sterile conditions, a 50 mm block needle will be advanced into the interscalen area using the in-plane method. After localization and negative aspiration, 15 ML of 5% bupivacaine drug will be injected into the interscalene area. 100 ml of NACI will be given intravenously within 15 minutes.~General anesthesia will be performed using 2 mg/kg of propofol and 1-2 µg/kg of fentanyl. Tracheal intubation will be facilitated with 0.6mg/kg rocuronium. Anesthesia will be maintained using 50% oxygen and 2% sevoflurane. Patients will be extubated into the operating room after reversing residual muscle relaxation. A multimodal analgesia regimen will be applied postoperatively.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group Dex
Description: Patients will receive 2 mg midazolam and 50 ug fentanyl for sedation before the block procedure. Each patient will be positioned appropriately, then a high-frequency linear array transducer (13-6 MHz) will be placed in the interscalene region to define the brachial plexus on the short axis. Under sterile conditions, a 50 mm block needle will be advanced into the interscalene area using the in-plane method. After localization and negative aspiration, 15 ML of 5% bupivacaine drug will be injected into the interscalene area. 5 mg dexamethasone intravenously will be given in 100 ml NACI within 15 minutes.~General anesthesia will be performed using 2 mg/kg of propofol and 1-2 µg/kg of fentanyl. Tracheal intubation will be facilitated with 0.6mg/kg rocuronium. Anesthesia will be maintained using 50% oxygen and 2% sevoflurane. Patients will be extubated into the operating room after reversing residual muscle relaxation. A multimodal analgesia regimen will be applied postoperatively.
Study: NCT05031533

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dose-Painting Radiation
Description: Radiation therapy:~1. Delineation of target area:~   The primary tumor is delineated into different target areas according to the anatomical position of the tumor, including the central area tumor GTV-Tcentral and GTV-Tperipheral.~2. Exposure dose:~1) GTV-Tcentral: 2.0～2.5Gy/f, bid, 10-13d, physical dose 40-65Gy 2) GTV-Tperipheral: 3.0～4.0Gy/f, bid, 10-13d, physical dose 60-104Gy 3) GTV-N (mediastinal lymph node): 2.0Gy/f, bid, 10-13d, physical dose 40-52Gy
Study: NCT06299176

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Heart Radiation Therapy
Description: Radiation to the whole heart in one treatment with a prescribed dose of 5 Gy.
Study: NCT06166329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chair lift test
Description: repetitions of the sit-stand position at a self-timed speed (safe and comfortable) as many times as possible for 1 minute
Study: NCT06370065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC+Serplulimab（HLX10）+ Bevacizumab Biosimilar（HLX04）
Description: PD-1 inhibitor
Study: NCT05922774

Intervention type: DEVICE
Intervention: Cervical VEMP testing
Description: cervical vestibular evoked myogenic potentials

Intervention type: DEVICE
Intervention: Cervical VEMP testing
Description: cervical vestibular evoked myogenic potentials

Intervention type: DEVICE
Intervention: Cervical VEMP testing
Description: cervical vestibular evoked myogenic potentials
Study: NCT05156606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AndroGel
Description: After the baseline imaging with FES- and FDHT-PET is completed, tamoxifen 20mg 1dd1 (standard dosage) plus testosterone (Androgel®) will be started. The first 3 patients will receive 25mg testosterone once daily (half the standard starting dosage for male hypogonadism). If this is well tolerated after 3 weeks, the dosage will be increased to 50mg once daily. Out of precaution, the safety profile of the 50mg dosage in the first 3 patients will be evaluated after all 3 patients have received 50mg testosterone for 2 cycli (8 weeks), prior to proceeding to the next 3 patients. Patients will be treated with tamoxifen and testosterone until disease progression or unacceptable toxicity.